Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed

NCT00006006 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

38

Enrollment

NIH

Sponsor class

Conditions

Liver Cancer

Interventions

BIOLOGICAL: recombinant interferon alfa
DRUG: thalidomide

Sponsor

National Cancer Institute (NCI)